Strong delivery, bold ₹1,500 Cr FY30 vision with concrete milestones
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade A
Delivered Q2 exactly as promised. Raised FY27 guidance ₹700→₹720 Cr. Track record of on-time execution on registrations.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong quarter (63% rev, 106% PAT) matched guidance exactly; FY27 target raised to ₹720 Cr. Pipeline visibility strong (19 BE studies complete, hormone/biologics roadmap clear). Multi-year ₹1,500 Cr FY30 target backed by concrete mechanisms. Key risk: regulatory approvals (FDA ANDA, EMA) not guaranteed; MENA concentration (~60% growth) creates geographic risk.
₹181.2 Cr
Revenue · +63.2% YoY₹29 Cr
Reported PAT · +105.6% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 FY27 revenue ₹181 Cr with 63% YoY growth
METDelivered ₹181.2 Cr, YoY +63.2%. Matches exactly.
PAT doubled; profit after tax ₹29 Cr
METDelivered ₹29.0 Cr, YoY +105.6% (doubled). Matches exactly.
EBITDA margin 27.5%
METDelivered 27.5% margin. Matches exactly.
H1 FY27 revenue ₹343 Cr; FY27 guidance ₹720 Cr
METRaised from ₹700+ to ₹720 Cr. H1 implies Q1 ~₹162 Cr. Guidance upgrade supported.
Strong product pipeline: 19 BE dossiers complete, 21 more by Q1 FY28
METDetailed roadmap: Mexico/Brazil Q4 FY27, Canada/Australia Q2 FY28. Specific timelines given.
Hormone commercialization Q3 FY28 at ₹100–150 Cr run-rate by FY29
METConservative ₹100–150 Cr disclosed; speculative but backed by process validation and audit completion.
Earnings quality
What changed since the last call
FY27 revenue guidance raised
UpgradePrior ₹700+ Cr → ₹720 Cr. Reflects strong MENA registrations and international momentum.
EBITDA margin guidance upgraded
UpgradeQ2 delivered 27.5% vs 26–27% prior range. Driven by high-margin international direct sales.
Working capital cycle sharply improved
UpgradeDebtor days down 208→178 days; overall cycle 170→130 days. Better collections and inventory management.
Unit 7 acquisition and bioequivalence roadmap
New4-acre land acquired for manufacturing; 200 BE studies planned. Phases in FY28, 29, 30.
The Q&A
Moderate. Analysts pressed on regulatory timelines (ANDA, EMA), hormone volume assumptions, and MENA concentration. Management held firm on conservative guidance (₹720 Cr, not ₹750+) but was transparent on risks. Acknowledged ₹60–70 Cr Middle East debtor stuck in Q4 FY26; resolved in Q1–Q2. No evasion, but some hedging on US biosimilar upside.
FY28–FY29 revenue path — Deepak Chokhani, Raedan Capital
AnsweredFY28 ₹950–1,000 Cr achievable; FY29 could easily cross ₹1,000 Cr if 30–35% growth materializes. European/Brazilian registrations + hormone will drive.
Bioequivalence molecules timeline — Nirali Shah, Ashika Investment Managers
AnsweredFirst 7–8 molecules commercialized in Latin America/Europe by Q4 FY27; Brazil Q2 FY28. By FY29, ₹80–100 Cr achievable; could reach ₹300 Cr by FY29 if registrations accelerate.
FY27 guidance conservatism — Abhijeet, 129 Wealth
Answered₹720 Cr conservative due to December holiday shutdown and international market closure until Jan 15. KPMG compliance costs also factored. ₹720–750 Cr range realistic, but taken conservative approach.
Margin sustainability — Darshil Jhaveri, Crown Capital
AnsweredDifferentiated portfolio (19–20 bioequivalences across segments) allows pricing power. New competitors don't deter; every year add 40 molecules. First generic or second generic leaders command premium margins.
ANDA timeline — Manan Vandur, Wallfort Fund Management
PartialANDA for cephalosporin and beta-lactam in progress. Not 100% sure US FDA will clear (stability studies ongoing). Will give guidance in Q1 FY28 when visibility improves.
Unit 7 revenue potential — Vivek Gupta, Advent Consulting
AnsweredUnit 7 completed in 3 phases (FY28, 29, 30). Can accommodate 200 BE-approved products across 40 countries. 3–4x increase in sales revenue from current capacity.
Volume vs value split — Saurabh Gupta, Financially Free
AnsweredMENA registrations (Algeria, Morocco, Tunisia, Mexico, Colombia) drove 63%. API costs up 4–5% but sustainable without raising finished prices due to low-margin product replacement.
CapEx and working capital needs — Utkarsh Somaiya, Eiko Quantum Solutions
AnsweredUnit 7: ₹200–250 Cr; bioequivalence studies + R&D facility another ₹200 Cr. PAT will increase ₹150–160 Cr over 2 years; internal accrual + bank loans will cover expansion.
Currency risk and margin guidance — Vedant S., Math Investments
Answered85% sourcing from India, 10–15% China; mostly hedged. Currency fluctuations have not impacted costing. R&D increase from 2.5% to 5–6% will come from incremental revenue growth, not margin compression.
Unit 5 biosimilar potential — Hemant Soni, Individual Investor
AnsweredEach biosimilar molecule >$50B market; erythropoietin alone ₹1,000–1,200 Cr potential if clinical done. FY29–FY30 could reach ₹800–900 Cr from this molecule alone.
Commercialization pipeline — Bharat Pathak, Individual Investor
PartialCapacity expansion funded by external partnerships. Kwality holds drug substance. Biosimilar capex ₹150–200 Cr funded by partners; no equity dilution planned.
Guidance
FY27 ₹720 Cr (raised from ₹700+ Cr guidance in Q1 call)
HighBased on H1 actual (₹343 Cr) and MENA registrations in hand. Holiday impact and international market closure Jan 15 factored. Conservative stance taken.
FY28 ₹950–1,000 Cr; FY29 could exceed ₹1,000 Cr with 30–35% growth
MediumDependent on hormone commercialization, BE molecule registrations in Brazil/Canada/Singapore/Australia. Currency/competitive headwinds could impact.
FY30 ₹1,500 Cr (multi-year ambition from prior call, reaffirmed)
MediumRequires flawless execution on biologics pipeline, hormone scale-up, and 200 BE molecule registrations across 40+ countries.
FY27 EBITDA margin 27–28% (was 26–27% prior guidance)
HighQ2 delivered 27.5%. Without hormone operating costs, maintains 27–28% range. Hormone ramp will dilute to ~20% until scale.
FY28–FY30 EBITDA margin 26–27% sustainable
MediumAssumes hormone reaches ₹100–150 Cr by FY29 (20% margin initially, scaling to 30%+). Portfolio diversification balances margin pressure.
Unit 7 bioequivalence facility ₹200–250 Cr over FY28–FY30
High3-phase plan: FY28 phase 1, FY29 phase 2, FY30 phase 3. Will accommodate 200 BE studies, 3–4x revenue upside.
Hormone facility, R&D, biosimilar CDMO ₹200+ Cr total
MediumBiosimilar capex externally funded by partners. Total R&D/hormone capex phased. Internal accrual + bank loans to fund.
Risks the call surfaced
Regulatory approval risk
HighUS FDA ANDA for cephalosporin not 100% confirmed; stability studies ongoing. EMA approval for cephalosporin/oncology facility also pending. Biosimilar clinical trials add 3–5 year timeline risk.
Geographic concentration
MediumMENA (Algeria, Morocco, Tunisia, Mexico, Colombia) accounts for ~63% of Q2 growth. Middle East debtor days were ₹60–70 Cr stuck in Q4 FY26 (resolved in Q1–Q2). Political instability, currency crises, or payment delays could impact.
Clinical trial execution risk
MediumHormone plant Q3 FY28 commercialization depends on clinical trial completion and PIC/S audit approval. Erythropoietin and biosimilar clinical trials are 3–5 year timelines; failure would derail FY30 ₹1,500 Cr target.
Currency and commodity volatility
Low85% API sourcing from India; 10–15% from China. INR depreciation could inflate costs. Though management reports hedging, if crude oil spikes, API prices rise (4–5% increase seen recently).
Execution risk on Unit 7 and bioequivalence facility
MediumUnit 7 (4 acres) must be built in 3 phases (FY28–FY30) to support 200 BE molecules. Construction delays, equipment lead times, or manufacturing yield issues could defer revenue.
Management
Score 7/10. Clear on numbers and timelines. Transparent on regulatory risks and acknowledged ₹60–70 Cr debtor issue. Less specific on US biosimilar ANDA timing; deferred visibility to Q1 FY28. Strong track record. Q2 delivered exactly as promised (₹181.2 Cr, ₹29 Cr PAT, 27.5% margin). Raised FY27 guidance ₹700→₹720 Cr. No prior guidance cuts or major misses cited.
1 · Q3 FY27
Hormone plant commercialization; first sales revenue ₹30–40 Cr potential.
2 · Q4 FY27
Cephalosporin registration in Mexico/Brazil; first revenue from new molecules.
3 · Q1 FY28
CDMO 27D model approval; Canadian registrations; biowaiver applications approved.
Key risk: regulatory approvals (FDA ANDA, EMA) not guaranteed; MENA concentration (~60% growth) creates geographic risk.
Informational and educational content only. Not investment advice.